Veracyte (VCYT) Competitors $31.76 -0.38 (-1.18%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$31.33 -0.43 (-1.35%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. HIMS, OPCH, GH, RDNT, BTSG, SHC, SGRY, PRVA, CON, and LFSTShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Hims & Hers Health (HIMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), and LifeStance Health Group (LFST). These companies are all part of the "healthcare" industry. Veracyte vs. Hims & Hers Health Option Care Health Guardant Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Privia Health Group Concentra Group Holdings Parent LifeStance Health Group Veracyte (NASDAQ:VCYT) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Do insiders & institutionals believe in VCYT or HIMS? 63.5% of Hims & Hers Health shares are held by institutional investors. 1.3% of Veracyte shares are held by company insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate VCYT or HIMS? Veracyte currently has a consensus price target of $42.60, suggesting a potential upside of 34.13%. Hims & Hers Health has a consensus price target of $38.25, suggesting a potential upside of 29.73%. Given Veracyte's stronger consensus rating and higher probable upside, research analysts clearly believe Veracyte is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Hims & Hers Health 2 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.21 Which has stronger valuation & earnings, VCYT or HIMS? Hims & Hers Health has higher revenue and earnings than Veracyte. Hims & Hers Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$445.76M5.55-$74.40M$0.30105.87Hims & Hers Health$1.48B4.44-$23.55M$0.5454.60 Is VCYT or HIMS more profitable? Hims & Hers Health has a net margin of 8.19% compared to Veracyte's net margin of -2.18%. Hims & Hers Health's return on equity of 10.97% beat Veracyte's return on equity.Company Net Margins Return on Equity Return on Assets Veracyte-2.18% 3.02% 2.80% Hims & Hers Health 8.19%10.97%8.29% Does the MarketBeat Community favor VCYT or HIMS? Veracyte received 407 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 73.05% of users gave Veracyte an outperform vote while only 36.44% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformVeracyteOutperform Votes45073.05% Underperform Votes16626.95% Hims & Hers HealthOutperform Votes4336.44% Underperform Votes7563.56% Which has more risk & volatility, VCYT or HIMS? Veracyte has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Does the media refer more to VCYT or HIMS? In the previous week, Hims & Hers Health had 11 more articles in the media than Veracyte. MarketBeat recorded 26 mentions for Hims & Hers Health and 15 mentions for Veracyte. Veracyte's average media sentiment score of 0.94 beat Hims & Hers Health's score of 0.73 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 14 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive SummaryHims & Hers Health beats Veracyte on 10 of the 18 factors compared between the two stocks. Remove Ads Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.48B$2.86B$5.33B$7.57BDividend YieldN/A31.37%5.11%4.32%P/E Ratio-211.7313.3521.7317.81Price / Sales5.55187.75379.2094.61Price / Cash442.2957.5638.1534.64Price / Book2.224.556.464.00Net Income-$74.40M-$22.21M$3.20B$247.23M7 Day Performance-2.64%2.20%2.85%1.45%1 Month Performance0.79%-1.18%-8.55%-6.24%1 Year Performance67.86%8.11%10.46%0.60% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte4.0071 of 5 stars$31.76-1.2%$42.60+34.1%+64.0%$2.48B$445.76M-211.73790Short Interest ↑HIMSHims & Hers Health3.5804 of 5 stars$27.71+6.6%$37.31+34.7%+123.0%$6.16B$1.48B62.97650OPCHOption Care Health3.134 of 5 stars$32.87-2.0%$33.00+0.4%+4.4%$5.40B$5.00B27.625,600Short Interest ↑Positive NewsGHGuardant Health3.6905 of 5 stars$41.78+3.0%$48.95+17.2%+162.9%$5.16B$739.02M-11.741,790RDNTRadNet3.8288 of 5 stars$49.29+1.2%$73.25+48.6%+11.0%$3.65B$1.83B-704.048,970Positive NewsHigh Trading VolumeBTSGBrightSpring Health Services2.9237 of 5 stars$17.28+0.8%$21.67+25.4%+64.4%$3.02B$11.27B-66.4635,000News CoverageGap DownSHCSotera Health2.4134 of 5 stars$10.23-1.1%$16.00+56.4%-4.6%$2.90B$1.10B40.923,000Gap DownSGRYSurgery Partners2.7624 of 5 stars$20.51-2.8%$36.63+78.6%-17.9%$2.62B$3.11B-42.7313,500Positive NewsGap DownPRVAPrivia Health Group3.7677 of 5 stars$21.48-2.2%$26.67+24.1%+31.8%$2.59B$1.74B214.82810Analyst ForecastHigh Trading VolumeCONConcentra Group Holdings ParentN/A$20.19-2.1%$28.50+41.2%N/A$2.57B$1.90B13.3711,000Positive NewsGap DownLFSTLifeStance Health Group1.9107 of 5 stars$6.51-2.0%$8.50+30.6%+16.6%$2.50B$1.25B-25.046,640Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Hims & Hers Health Competitors Option Care Health Competitors Guardant Health Competitors RadNet Competitors BrightSpring Health Services Competitors Sotera Health Competitors Surgery Partners Competitors Privia Health Group Competitors Concentra Group Holdings Parent Competitors LifeStance Health Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VCYT Stock Free VCYT Stock Alerts